Please check your internet connection and try again.
## Att0drugs
### Overview
Att0drugs is a broad-spectrum antibiotic effective against a wide range of gram-positive and gram-negative bacteria. It functions by inhibiting bacterial protein synthesis.
### Primary Indications
* Treatment of moderate to severe bacterial infections, including pneumonia, skin and soft tissue infections, and intra-abdominal infections.
* Prophylaxis against certain infections in specific patient populations.
### Adult Dosing
* **Pneumonia and Skin/Soft Tissue Infections:** 500 mg orally every 12 hours for 7-14 days, or 500 mg intravenously every 12 hours for 7-10 days.
* **Intra-abdominal Infections:** 750 mg orally every 12 hours for 7-14 days, or 750 mg intravenously every 12 hours for 5-14 days.
* Maximum daily dose: 1500 mg (oral) or 2250 mg (IV).
### Pediatric Dosing
* Dosing in pediatric patients is based on weight and indication. Specific protocols should be consulted. General guidelines:
* **1 month to 12 years:** 5-10 mg/kg/dose orally every 12 hours, not to exceed adult doses.
* **1 month to 12 years (severe infections):** 10-15 mg/kg/dose intravenously every 8-12 hours, not to exceed adult doses.
* Consult specific pediatric guidelines or local protocols for precise dosing.
### Dose Adjustments
* **Renal Impairment:**
* CrCl > 30 mL/min: No dose adjustment needed.
* CrCl < 30 mL/min: Reduce dose by 50%. For IV administration, consider extending the dosing interval to every 24 hours.
* Hemodialysis/Peritoneal Dialysis: Administer dose after dialysis. Dose adjustment as for CrCl < 30 mL/min.
* **Hepatic Impairment:** No dose adjustment typically required.
### Contraindications
* Hypersensitivity to Att0drugs or other macrolides.
* Concurrent use with certain medications that prolong the QT interval (e.g., amiodarone, quinidine, dofetilide).
### Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal pain, headache.
* **Serious:** QT prolongation, *Clostridioides difficile*-associated diarrhea, hepatotoxicity, allergic reactions.
### Key Drug Interactions
* **CYP3A4 Inhibitors:** Att0drugs is a substrate of CYP3A4. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can increase Att0drugs levels and risk of adverse effects.
* **CYP3A4 Substrates:** Att0drugs can inhibit CYP3A4, potentially increasing serum concentrations of drugs metabolized by this enzyme (e.g., simvastatin, atorvastatin, cyclosporine, tacrolimus, warfarin). Monitor closely and adjust doses as needed.
* **QT Prolonging Agents:** Increased risk of QT prolongation and arrhythmias.
### Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Assess for effectiveness of treatment (e.g., reduction in fever, improvement in infection markers).
* Monitor for signs of *C. difficile*-associated diarrhea (e.g., persistent diarrhea, abdominal cramping, fever).
* Consider baseline and periodic liver function tests, especially with prolonged therapy or in patients with pre-existing hepatic disease.
* Monitor electrolytes and ECGs in patients at risk for QT prolongation.
### Clinical Pearls
* Att0drugs can be taken with or without food.
* For IV administration, reconstitute and dilute according to manufacturer instructions. Infuse over at least 60 minutes.
* Educate patients on the importance of completing the full course of therapy, even if symptoms improve.
* Advise patients to report any severe or persistent gastrointestinal symptoms.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and your institution's protocols before making treatment decisions. Dosing and recommendations may vary.*
